Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)

Active, not recruitingOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

February 28, 2022

Study Completion Date

January 20, 2025

Conditions
Sarcoma
Interventions
GENETIC

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and MGMT expression on dacarbazine treated sarcoma patients

"Tumor samples of Leiomyosarcoma and Solitary Fibrous Tumours patients, dacarbazine (as single agents or in combination with anthracyclines) treated, will be obtained from and characterized by the Pathology Unit of the Istituto Nazionale Tumori Fondazione Pascale in Naples, Campus Biomedico of Rome, Istituto Oncologico of Bari and University of Palermo.~Glioblastomas control samples will be obtained from CEINGE-Biotecnologie Avanzate, in Naples and characterized by the Pathology Unit of the University of Naples Federico II.~After biopsy or surgical resection, the tissues were fixed in 10% formalin and included in paraffin blocks. All patients partecipating in this study provided informed consent."

Trial Locations (1)

80131

National Cancer Institute of Naples, Naples

All Listed Sponsors
lead

National Cancer Institute, Naples

OTHER